Expert opinion on pharmacotherapy · 2025
Investigating cefepime/taniborbactam for the treatment of complicated urinary tract infections.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bartalucci Claudia, Giurco Marianna, Vena Antonio, Giacobbe Daniele Roberto, Bassetti Matteo
Аннотация
INTRODUCTION: The spread of multidrug-resistant (MDR) Gram-negative bacteria, such as carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, has led to a pressing need for novel treatment options. Cefepime/taniborbactam is a new β-lactam/β-lactamase inhibitor combination showing activity against a broad spectrum of β-lactamases, also including carbapenemases of different classes.
AREAS COVERED: In this narrative review, we discuss the preclinical and clinical evidence on cefepime/taniborbactam, including in vitro activity, pharmacokinetic/pharmacodynamic studies, and efficacy and safety data from randomized controlled trials.
EXPERT OPINION: Cefepime/taniborbactam demonstrates promising in vitro activity against a broad range of β-lactamase-producing bacteria, such as carbapenemase-producing Enterobacterales, including those producing metallo-β-lactamases, and difficult-to-treat Pseudomonas aeruginosa. Its efficacy and safety profile in complicated urinary tract infections suggest that it could represent a valuable therapeutic option, particularly in settings with high prevalence of difficult-to-treat pathogens.
AREAS COVERED: In this narrative review, we discuss the preclinical and clinical evidence on cefepime/taniborbactam, including in vitro activity, pharmacokinetic/pharmacodynamic studies, and efficacy and safety data from randomized controlled trials.
EXPERT OPINION: Cefepime/taniborbactam demonstrates promising in vitro activity against a broad range of β-lactamase-producing bacteria, such as carbapenemase-producing Enterobacterales, including those producing metallo-β-lactamases, and difficult-to-treat Pseudomonas aeruginosa. Its efficacy and safety profile in complicated urinary tract infections suggest that it could represent a valuable therapeutic option, particularly in settings with high prevalence of difficult-to-treat pathogens.